Status:
UNKNOWN
Multimodal Analgesia in Laparoscopic Radical Gastrectomy With Gastric Cancer: a Multi-center Study
Lead Sponsor:
JIANG Zhi-Wei
Collaborating Sponsors:
Pfizer
Conditions:
Gastric Cancer
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The study is aimed to explore the effects of multimodal analgesia consisting of ropivacaine's wound infiltration, parecoxib's intravenous injection and oxycodone-acetaminophen tablets' oral administra...
Detailed Description
Postoperative pain attracts the attention of surgeons, and optimal postoperative pain management contributes to reducing complications and accelerating postoperative rehabilitation. Traditionally, the...
Eligibility Criteria
Inclusion
- Requirements of informed consent and assent of participant, parent or legal guardian as applicable.
- Patients underwent laparoscopic radical gastrectomy under general anesthesia and between the age of 18 and 75 years old without considering sex.
- American Society of Anesthesiologists (ASA) physical status I-III.
- Participants can follow the drug doses and visit plan
Exclusion
- Patients certified by a doctor that doesn't fit to participate in this study.
- Patients allergic to opioids, sulfas, parecoxib, non-steroidal drugs, acetaminophen, tramadol etc..
- Patients with ischemic heart disease, cerebrovascular disease and peripheral vascular disease, or their cardiac function \> II (NYHA) patients, patients received coronary artery bypass grafting (CABG) recently, and patients with severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110mmHg).
- Patients with gastric cancer with distant metastasis.
- Patients with severe infection, respiratory dysfunction, coagulation disorders, severe liver and renal dysfunction (Child - Pugh≥ 10; creatinine clearance \< 25 ml/min).
- Patients with suspect or have a history of drug abuse.
- Pregnancy and lactation women, or have a pregnancy plan within a month after the test of the subjects (also including male participants).
- Sponsors or researchers directly involved in the testing or their family members.
- Patients with conversion, palliative resection.
- Patients with chronic pain（NRS≥3）or using opioids or NSAIDs before surgery.
Key Trial Info
Start Date :
February 10 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2018
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT03236051
Start Date
February 10 2017
End Date
August 30 2018
Last Update
August 1 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Jinling Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China, 210002
2
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210011